AASLD: Once-Daily HCV Protease Inhibitors Show Early Promise (CM...

Courtesy MedPage Today Infectious Disease  Tue, 11/03/2009 - 10:26

BOSTON (MedPage Today) -- Two investigational drugs targeting the hepatitis C virus (HCV) protease enzyme helped patients clear the virus with once-daily dosing, in contrast with the three-times-per-day schedule needed for similar drugs in development.


 

More related items

AASLD: High SVR Rates Seen with Telaprevir for...
BOSTON (MedPage Today) -- Availability of direct antiviral drugs for hepatitis C virus (HCV) infection moved another step closer to realization, with favorable results reported here for...

AASLD: HCV Response Linked Strongly to Gene Variant...
BOSTON (MedPage Today) -- Additional analysis has confirmed that a polymorphism in an interferon-related gene is strongly associated with responses to standard treatments for hepatitis C...

AASLD: Direct Antivirals Can Beat HCV Without...
BOSTON (MedPage Today) -- The first clinical trial of direct antiviral drugs against hepatitis C virus (HCV) without interferon was a success, researchers said, though the FDA currently won't...

Nasaline Nasal Irrigator
The easy, comfortable, and safe method to irrigate your nasal cavities with saline solution to effectively treat symptoms associated with allergies, colds or the flu features: -the syringe...

Wahl 9877-500 "The Goatee" Advanced Dual Blade,...
The Wahl Goatee Trimmer features precision ground high carbon steel blades that stay sharp and give you the perfect trim every time. Easily tighten up your beard, mustache, goatee, and...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
health-fitness.marc8.com